BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 865 filers reported holding BAXTER INTL INC in Q3 2016. The put-call ratio across all filers is 0.50 and the average weighting 0.3%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $318,034 | -16.1% | 8,365 | +1.2% | 0.02% | -13.8% |
Q2 2023 | $378,987 | +6.0% | 8,265 | -5.5% | 0.03% | 0.0% |
Q1 2023 | $357,487 | -22.4% | 8,750 | -2.6% | 0.03% | -27.5% |
Q4 2022 | $460,731 | -11.4% | 8,985 | -6.4% | 0.04% | -20.0% |
Q3 2022 | $520,000 | -14.8% | 9,595 | +1.5% | 0.05% | -5.7% |
Q2 2022 | $610,000 | -22.0% | 9,453 | -5.8% | 0.05% | -8.6% |
Q1 2022 | $782,000 | -24.0% | 10,040 | -15.9% | 0.06% | -22.7% |
Q4 2021 | $1,029,000 | +7.2% | 11,945 | +0.5% | 0.08% | 0.0% |
Q3 2021 | $960,000 | +2.6% | 11,891 | +2.3% | 0.08% | -10.7% |
Q2 2021 | $936,000 | +201.9% | 11,624 | +216.5% | 0.08% | +180.0% |
Q1 2021 | $310,000 | +5.1% | 3,673 | 0.0% | 0.03% | -6.2% |
Q4 2020 | $295,000 | 0.0% | 3,673 | 0.0% | 0.03% | -13.5% |
Q3 2020 | $295,000 | -6.6% | 3,673 | 0.0% | 0.04% | -11.9% |
Q2 2020 | $316,000 | +6.0% | 3,673 | 0.0% | 0.04% | -14.3% |
Q1 2020 | $298,000 | -16.1% | 3,673 | -13.6% | 0.05% | +11.4% |
Q4 2019 | $355,000 | -5.3% | 4,250 | -0.8% | 0.04% | -12.0% |
Q3 2019 | $375,000 | +1.1% | 4,285 | -5.5% | 0.05% | -2.0% |
Q2 2019 | $371,000 | -52.9% | 4,535 | -53.2% | 0.05% | -7.3% |
Q1 2019 | $788,000 | +145.5% | 9,700 | +99.2% | 0.06% | +5.8% |
Q4 2018 | $321,000 | -14.4% | 4,870 | 0.0% | 0.05% | 0.0% |
Q3 2018 | $375,000 | -0.8% | 4,870 | -4.8% | 0.05% | -7.1% |
Q2 2018 | $378,000 | +75.0% | 5,115 | +54.3% | 0.06% | +75.0% |
Q1 2018 | $216,000 | -3.6% | 3,315 | -4.4% | 0.03% | 0.0% |
Q4 2017 | $224,000 | -2.6% | 3,467 | -5.6% | 0.03% | -8.6% |
Q3 2017 | $230,000 | +3.6% | 3,672 | 0.0% | 0.04% | 0.0% |
Q2 2017 | $222,000 | -73.0% | 3,672 | -79.8% | 0.04% | -75.5% |
Q2 2016 | $821,000 | +10.2% | 18,145 | 0.0% | 0.14% | +11.7% |
Q1 2016 | $745,000 | +4.3% | 18,145 | -3.0% | 0.13% | +4.9% |
Q4 2015 | $714,000 | +17.2% | 18,703 | +0.8% | 0.12% | +14.0% |
Q3 2015 | $609,000 | -54.5% | 18,553 | -3.1% | 0.11% | -50.2% |
Q2 2015 | $1,338,000 | +1.7% | 19,138 | -0.3% | 0.22% | +3.9% |
Q1 2015 | $1,315,000 | -8.5% | 19,190 | -2.2% | 0.21% | -9.2% |
Q4 2014 | $1,437,000 | -1.1% | 19,612 | -3.1% | 0.23% | -1.7% |
Q3 2014 | $1,453,000 | +1.0% | 20,242 | +1.7% | 0.23% | +0.9% |
Q2 2014 | $1,439,000 | -3.2% | 19,897 | -1.5% | 0.23% | -7.3% |
Q1 2014 | $1,486,000 | +7.7% | 20,197 | +1.8% | 0.25% | +8.8% |
Q4 2013 | $1,380,000 | +11.4% | 19,847 | +5.3% | 0.23% | +1.3% |
Q3 2013 | $1,239,000 | +24.4% | 18,857 | +31.2% | 0.22% | +21.6% |
Q2 2013 | $996,000 | – | 14,372 | – | 0.18% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Point | 41,000,000 | $2,482,140,000 | 22.00% |
THUNDERBIRD PARTNERS LLP | 1,711,643 | $103,623,000 | 12.17% |
SECTOR GAMMA AS | 1,070,333 | $64,798,000 | 9.42% |
Veritas Asset Management LLP | 10,179,102 | $616,243,000 | 4.81% |
13D Management LLC | 194,807 | $11,794,000 | 4.18% |
Progressive Investment Management Corp | 78,316 | $4,741,000 | 3.69% |
Aristotle Capital Management, LLC | 6,846,307 | $414,476,000 | 3.46% |
ARGENT CAPITAL MANAGEMENT LLC | 1,394,075 | $84,397,000 | 3.37% |
Lipe & Dalton | 80,073 | $4,848,000 | 3.14% |
PURA VIDA INVESTMENTS, LLC | 125,000 | $7,568,000 | 3.00% |